Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa (MTBVACN3)
Tuberculosis
About this trial
This is an interventional prevention trial for Tuberculosis
Eligibility Criteria
Inclusion Criteria:
- Male or female newborns within seven days of birth.
- Written informed maternal consent, including permission to access maternal antenatal, postnatal, and infant medical records.
- Infant participants and their caregivers available for trial follow-up and display the willingness and capacity to comply with trial procedures.
- Newborns must be in good general health during pregnancy and delivery, as assessed by medical history and targeted physical examination.
- Birth weight ≥ 2450 grams.
- Apgar score at 5 minutes ≥ 7.
- A maternal HIV test result (rapid test, enzyme-linked immunosorbent assay (ELISA), or Polymerase chain reaction (PCR)) taken within 30 days of delivery, or within seven days post-partum must be available and documented if HIV uninfected. If the mother is HIV infected, then she must be on antiretroviral (ARV) therapy as per in-country guidelines with a viral load of <50 copies/mL (within six months of labour).
- Estimated gestational age ≥ 37 weeks.
- Mother has not participated in a clinical trial within three months prior to the infant's birth.
- Mother has never participated in a TB vaccine trial before.
- Infant may not participate in any other clinical trials.
Exclusion Criteria:
Receipt of BCG vaccination prior to enrolment.
- Significant antenatal, intrapartum, or postpartum complications that may affect the health of the newborn.
- Skin condition, bruising or birth mark at the intended injection site.
- Maternal HIV test (rapid test, ELISA, or PCR) result not available.
- HIV exposed Newborn's HIV PCR result positive or not available.
- Maternal history of TB during pregnancy.
- History of close/household contact with a TB patient, antenatal or postnatal, whether maternal, other family member or another household member who has not yet completed TB treatment.
- Clinically suspected neonatal sepsis.
- Any severe congenital malformation.
- History or evidence of any systemic disease on examination, or any illness that in the opinion of the Investigator may interfere with the evaluation of the safety and immunogenicity of the vaccine. Neonatal jaundice not considered clinically significant is not an exclusion.
Sites / Locations
- South African Tuberculosis Initiative, Brewelskloof HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
MTBVAC
BCG
Both MTBVAC and BCG vaccines are administered by intradermal route in the left deltoid region. One 0.05 mL reconstituted dose of MTBVAC will be defined based on the phase IIa results. MTBVAC is manufactured by Biofabri. MTBVAC is formulated (1.5 - 8.5 x104 CFU/dose, 1.5 - 8.5 x105 CFU/dose or 1.5 - 8.5 x106 CFU/dose (to be selected) and presented as a lyophilised pellet in 20 dose vials (0.05 mL/dose, after reconstitution with sterile water for injection). MTBVAC vaccine will be released and distributed by BIOFABRI, and imported to the sites following approval by the local regulatory authority. MTBVAC vaccine must be stored at +2°C to +8°C. Reconstituted MTBVAC vaccine must be stored at +2ºC to +8ºC and administered as soon as possible, within 4 hours of reconstitution. A single vaccine vial will be used for each participant.
BCG is a live attenuated M. bovis strain developed 100 years ago and is used as a preventive vaccine against tuberculosis. It is administered at birth. One 0.05 mL reconstituted dose of BCG contains 2.5 x 105 CFU. The control vaccine will be the BCG vaccine available and recommended in South Africa at time of the trial. BCG vaccine produced by AJ Biologics (formerly Staten Serum Institute) is the only BCG vaccine (Danish strain) currently licensed for routine use in South Africa. The recommended BCG injection volume for newborn infants (0.05 mL, after reconstitution with BCG diluent) contains approximately 2.5 x 105 CFU (range 1-4 x 105 CFU). BCG vaccine vials should be stored in the site pharmacy at 2-8ºC.